Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp rugada syndrome (BrS) is a hereditable disorder characterized by ST-segment elevations in the right precordial electrocardiogram (ECG) leads, associated with a high incidence of syncope or sudden death due to ventricular tachyarrhythmias, which mostly affects men. BrS is genetically heterogeneous, and has been linked to mutations in genes that perturb cardiac ion currents (INa, ICa, IK-ATP and Ito) contributing to the early phase of action potential (AP). 1-12 Among the BrScausing genes, mutations in SCN5A (encoding the pore-forming α-subunit of the cardiac voltage-gated sodium channel) have accounted for the major form of BrS in approximately 20% of cases, and other gene mutations for approximately 10%, 1-12 thus around 70% of BrS cases remain to be geneti-cally elucidated.
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cordial ECG leads (Brugada-pattern ECG) in BrS. 14 Further augmentation of the AP notch in epimyocardium causes the loss of AP plateau phase (dome), which consequently leads to arrhythmogenesis in BrS defined as phase 2 reentry. 14 Ito in human ventricle is thought to be consist of α-subunit Kv4.3 (encoded by KCND3) and β-subunits including Kv channel interacting protein (KChIP), KCNE, diaminopeptidyl transferase-like protein (DPP) and Kvβ families. [16] [17] [18] [19] [20] [21] [22] [23] [24] Accordingly, mutations in the related genes that increase Ito may underlie the pathogenesis of BrS. KCNE3, 1 member of the KCNE gene family (KCNE1-5), modulates the function of Kv4.3 as an inhibitory β-subunit. 19, 20 Recently, Delpón et al identified a KCNE3 R99H mutation in 1 BrS family. 6 Functional analysis using the heterologous expression system that recapitulates Ito by coexpression of Kv4.3 with KCNE3-wild type (WT)/R99H showed that KCNE3 R99H causes a gain of function of Ito by a dominant-positive effect, thus precipitating the development of BrS. 6 Moreover, mutations in Kv4. 3 and KCNE5, which also functions as an inhibitory β-subunit of Ito, were identified in BrS patients. 9,10 Functional analysis of these mutations showed that they increase Ito. 9,10 Therefore, it was established that the gain of function of Ito by mutations in genes that encode Ito could be one of the causes of BrS.
We have previously reported the identification of 8 mutations in SCN5A among 30 consecutive Japanese patients with Brugada-pattern ECG. 25 Considering that the genetic heterogeneity of BrS is poorly elucidated in Japan, 10,26, 27 we further conducted genetic screening of BrS-causing genes among the 30 consecutive patients and another 10 new patients with Brugada-pattern ECG, and identified a KCNE3 T4A mutation in a patient presenting with neurally mediated syncope (NMS). In the present study, we describe the clinical phenotype of the KCNE3 T4A carrier, and characterize the functional consequence of the Ito recapitulated by heterologously coexpressing Kv4.3 + KChIP2b + KCNE3-T4A in CHO cells. Furthermore, we performed computer simulations based on the Ito obtained in electrophysiological recordings, and showed that KCNE3-T4A recapitulated the ECG phenotype.
Methods

Subjects
The present subjects were 40 consecutive patients (probands; 35 male, 47±16 years of age) with Brugada-pattern ECG who were referred to Gunma University Hospital between April 2002 and September 2010. All patients, except for patient 27, presented with coved-type ST-elevation in the right precordial ECG leads with or without provocation of Na channel blocker (pilsicainide: 1 mg/kg, or procainamide 5 mg/kg), although it is still under debate whether patients with drug-induced Brugadapattern ECG have poor prognosis. 28,29 Echocardiography and conventional left catheterization, if performed, indicated no structural heart disease in all the patients. Thirty-two patients underwent electrophysiological assessment. Up to 3 extra stimuli (minimum coupling interval: 180 ms) were delivered from 2 ventricular sites (right ventricular apex and right ventricular outflow tract). A head-up tilt (HUT) test was performed using the same protocol as described previously. 30 Clinical features of the subjects are listed in Table 1 .
Genetic Analysis
After obtaining appropriate approval from the institution review board and written informed consent from the patient, genomic DNA was extracted from peripheral blood lymphocytes using the standard protocol of the QIAamp DNA Blood Midi Kit (QIAGEN, Hilden, Germany). All coding exons of SCN5A, SCN1B, KCNE3, SCN3B and KCNE5, and their splice sites were amplified on polymerase chain reaction (PCR) using primers flanking the intronic sequences as reported previously. 1,5-7,25, 31 The PCR products were purified and directly sequenced using an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Regarding patient 18, CACNA1C and CACNB2 were also analyzed. 4 The mutation was analyzed twice on independent PCR amplification and sequencing. KCNE3 T4A was not identified in 528 control alleles.
Heterologous Expression of hKv4.3 and β-Subunits in CHO Cells
Full-length cDNA fragment of WT KCNE3 in pCR3.1 vector was subcloned into pIRES-CD8 vector that is useful in cell selection. The KCNE3 mutant (T4A) was constructed using a Quick Change II XL site-directed mutagenesis kit according to the manufacturer's instructions (Stratagene, La Jolla, CA, USA) and subcloned to the same vector. The KCNE3 mutant was fully sequenced (ABI PRISM 3130 Genetic analyzer) to ensure fidelity. Full-length cDNA encoding the short isoform of human Kv4.3 (hKv4.3) subcloned into the pIRES-GFP (Clontech, Palo Alto, CA, USA) expression vector was kindly provided by Dr GF Tomaselli (Johns Hopkins University). Full-length cDNA encoding Kv channel-interacting protein 2b (KChIP2b) subcloned into the PCMV-IRS expression vector was a kind gift from Dr GN Tseng (Virginia Commonwealth University). Kv4.3 was transiently transfected into CHO cells together with KChIP2b and KCNE3-WT (or T4A) cDNA at equimolar ratio (Kv4.3, 1.0 μg; KChIP2b, 1.0 μg; KCNE3, 1.0 μg) using Lipofectamine (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. In a subset of experiments, 0.5 μg KCNE3-WT and 0.5 μg KCNE3-T4A were co-transfected into cells with 1.0 μg Kv4.3 and 1.0 μg KChIP2b. The transfected cells were then cultured in Ham's F-12 medium (Nakalai Tesque, Kyoto, Japan) as described previously. 24
Electrophysiologic Recording and Data Analysis
After 48 h of transfection, a coverslip with cells was transferred to a 0.5-ml bath chamber at 25°C on an inverted microscope stage and perfused at 1-2 ml/min with extracellular solution containing the following (in mmol/L): 140 NaCl, 5.4 KCl, 1.8 CaCl2, 0.5 MgCl2, 0.33 NaH2PO4, 5.5 glucose, and 5.0 HEPES; pH 7.4 with NaOH. Cells that emitted green fluorescence were chosen for patch-clamp experiments. If coexpressed with KCNE3 (or its mutant), the cells were incubated with polystyrene microbeads precoated with anti-CD8 antibody (Dynabeads M450, Dynal, Norway) for 15 min. In these cases, cells that emitted green fluorescence and had attached beads were chosen for electrophysiologic recording. Whole-cell membrane currents were recorded with an EPC-8 patch-clamp amplifier (HEKA, Lambrecht, Germany), and data were low-pass filtered at 1 kHz, acquired at 5 kHz through an LIH-1600 analog-todigital converter (HEKA), and stored on hard disk using Puls-eFit software (HEKA). Patch pipettes had a resistance of 2. Whole cell currents were elicited in a series of depolarizing voltage steps from a holding potential of -80 mV. The time KCNE3 T4A Causes Brugada-Pattern ECG interval between each voltage pulse was 10 s. The difference between the peak current amplitude and the current at the end of a test pulse was referred to as the transient outward current.
To control for cell size variability, currents are expressed as densities (pA/pF) as described previously. 24 Steady-state activation curves were obtained by plotting the normalized conductance as a function of peak outward potentials. Steady-state inactivation curves were generated by a standard 2-pulse protocol with a conditioning pulse of 500 ms and obtained by plotting the normalized current as a function of the test potential. Steady-state inactivation/activation kinetics were fitted to the following Boltzmann equation:
where Y = normalized conductance or current, V1/2 = potential for half-maximum inactivation or activation, respectively, and k = slope factor. Data relative to inactivation time constants, time to peak, and mean current levels were obtained using current data recorded at +50 mV. Recovery from inactivation was assessed using a standard paired-pulse protocol: a 1-s test pulse to +50 mV (P1) followed by a variable recovery interval at -80 mV and then a second test pulse to +50 mV (P2). Both the inactivation time constants and the time constant for recovery from inactivation were determined by fitting the data to a single exponential:
where I(t) = current amplitude at time t, A and B = constants, and τ = inactivation time constant or time constant for recovery from inactivation. For measurement of recovery from inactivation, the plot of P2/P1 instead of I(t) was used.
All data are given as mean ± SEM. Statistical comparisons between 2 groups were analyzed using Student's unpaired ttest. Comparisons among multiple groups were analyzed using analysis of variance followed by Dunnett test. P<0.05 was considered significant.
Computer Simulation
To confirm the exact role of the KCNE3 T4A mutation, we conducted simulations of paced propagation in a 0.5-cm 1-D bidomain myocardial model with transverse conductivity, mimicking transmural section of right ventricular wall. Membrane kinetics were represented by the Priebe-Beuckelmann human ventricular model, 32 of which original Ito was replaced by the Ito with KCNE3-WT or KCNE3-T4A mutation obtained in electrophysiologic recording.
To obtain the transmural gradient in the right ventricular wall, we defined endocardial and epicardial tissues as each of length 0.25 cm, and we set the conductances of the slowly activating component of the delayed rectifier potassium channel (IKs), the inward rectifier potassium channel (IK1), and Ito in the endocardial layers to 46%, 82%, and 29%, respectively, of those in the epicardial layers. Pacing stimuli of 2 ms and strength twice-diastolic threshold were applied transmembranously to the endocardial end at a cycle length of 1,000 ms. The time and spatial discretization steps were 10 μs and 50 μm, respectively. Other model parameters and the numerical approach have been described elsewhere. 33 
Results
Genetic Analysis
We conducted comprehensive genetic analysis of BrS-causing genes including SCN5A, SCN1B, KCNE3, SCN3B and KCNE5, among 40 consecutive patients with Brugada-pattern ECG. Besides identifying 8 SCN5A mutations in the present cohort, we also found a T4A mutation in KCNE3 in the patient 18 who had no mutations in the other genes (including CACNA1C and CACNB2) associated with BrS ( Figure 1A; Table 1 ). 
Clinical Presentation
A 55-year-old man (patient 18) was referred to hospital to examine the cause of syncope. He had experienced several episodes of syncope under specific conditions, such as when sitting at a funeral, and standing up after drinking alcohol, since his 30 s. He had no previous history of illness except for syncopal episodes, and no family history of sudden cardiac death. A physical examination, chest X-ray, and blood test showed no remarkable abnormalities. His 12-lead ECG, recorded 2 months before admission, showed saddle-back-type ST-segment elevation in the right precordial ECG leads (Figure 1B) . The QTc interval was 414 ms. A coved-type ST-segment elevation in the right precordial ECG leads at the second intercostal space appeared after provocation with pilsicainide ( Figure 1C) . Signal-averaged ECG showed no late potentials. Transthoracic echocardiography showed no apparent structural heart disease.
The patient underwent electrophysiological assessment. Up to 3 extrastimuli induced non-sustained polymorphic ventricular tachycardia, but not ventricular fibrillation. An HUT test was performed because syncopal episodes had occurred under specific conditions that could evoke NMS. The HUT test during passive tilt provoked both hypotension and bradycardia, followed by syncope. Therefore, the patient was diagnosed as having NMS. The patient was not prescribed medication or implanted with an implantable cardioverter defibrillator.
KCNE3-T4A Mutation Increased the Current Amplitude of the Kv4.3 + KChIP2b + KCNE3 Channel
Because KCNE3 was shown to co-associate with Kv4.3 in the human heart, and Ito is thought to underlie the development of Brugada phenotype, 6,15 KCNE3-WT/T4A was coexpressed together with Kv4.3 and KChIP2b, which has been shown to serve as a principal β-subunit of Ito. 18,19,34,35 Figure 2A shows representative whole-cell current traces recorded from CHO cells expressing Kv4.3 + KChIP2b, Kv4.3 + KChIP2b + KCNE3-WT and Kv4.3 + KChIP2b + KCNE3-T4A.
Consistent with the previous literature, coexpression of KCNE3-WT dramatically reduced the current amplitude of the Kv4.3 + KChIP2b channel. 6,20,24 Further analysis of peak current showed that the current density of the coexpression with the KCNE3-T4A mutant was significantly larger than that for KCNE3-WT (Kv4.3 + KChIP2b + KCNE3-WT, 51.7±7.3 pA/ pF, n=25 vs. Kv4.3 + KChIP2b + KCNE3-T4A, 80.2±9.1 pA/ pF, n=22, P<0.05; Figure 2A,B) . Figure 2C shows mean time interval from the onset of the pulse to maximum current (time to peak), and Figure 2D shows the time constants (τ) of inactivation obtained using a single exponential at +50 mV. These data indicate that KCNE3-T4A mutation increased the current amplitude of the Kv4.3 + KChIP2b + KCNE3 channel, but did not affect time to peak and the inactivation time course.
Effect of KCNE3-T4A on Activation/inactivation Kinetics of Kv4.3 + KChIP2b + KCNE3 Channels
To further examine the effect of KCNE3-T4A on gating kinet- Coexpression of KCNE3-T4A (at -20 to +50 mV) or KCNE3-WT + KCNE3-T4A (at 0 to +50 mV) significantly increased peak current densities ( Figure 3A; Table 2 ). Meanwhile, coexpression of KCNE3-T4A, but not KCNE3-(T4A + WT), also caused a negative shift (approximately -5 mV) of voltage dependence of steady-state activation as assessed by plotting the normalized conductance as a function of test potentials (Figure 3B; Table 2 ). Figure 3C shows the representative current traces elicited by a double-step pulse method (inset) used to evaluate steadystate inactivation. Peak currents recorded at various levels of pre-pulse (Figure 3C) were normalized by that measured after a 500-ms pre-pulse at -90 mV and plotted as a function of prepulse test potentials (Figure 3D) . Coexpression of KCNE3-T4A or KCNE3-(WT + T4A) with Kv4.3 + KChIP2b did not significantly modify the steady-state inactivation of Kv4.3 + KChIP2b + KCNE3 channels (Figure 3D; Table 2 ).
Because the changes in the time course of reactivation can also affect Ito current, a double-pulse protocol (Figure 4A ) was used to test the effect of KCNE3-T4A or KCNE3-(WT + T4A) coexpression on the time course for recovery from inactivation. Figures 4A,B shows the representative current traces for coexpression of KCNE3-WT and KCNE3-T4A. Figure 4C shows the time courses of recovery of KCNE3-WT, KCNE3-T4A and KCNE3-(WT + T4A) coexpression together with Kv4.3 + KChIP2b. Time constants (τ) of recovery from inactivation are listed in Table 2 . Coexpression of KCNE3-T4A or KCNE3-(WT + T4A) did not affect the time course of recovery from inactivation.
Phenotype of KCNE3-T4A Mutation in a Simulated Human Right Ventricular Wall Model
To clarify whether the gain of function of Ito resulting from KCNE3-T4A mutation is indeed responsible for the Brugadapattern ECG, we performed computer simulations using the 1-D myocardial model of human right ventricular wall. Based on the Ito obtained in electrophysiologic recording (Figures 3A,B,D) , we numerically reproduced the current-voltage relationship curves (Figure 5A) , the normalized conductance-voltage relationship curves (Figure 5B) , and the steadystate inactivation curves (Figure 5C ) of the KCNE3-WT and KCNE3-T4A channels. The numerically reproduced Ito was incorporated into the 1-D right ventricular wall model, consisting of endocardial and epicardial layers (Figure 5D ). We found that the difference in the phase 2 AP between endocardial and epicardial layers in the KCNE3-T4A model was larger than that in the KCNE3-WT model, and therefore the simulated right precordial ECG showed ST-segment elevation in the case of KCNE3-T4A (Figure 5E) .
To examine the adequacy of the KCNE3-T4A model, we additionally conducted simulations with sodium channel blockade. In the case of KCNE3-WT (Figure 5F) , because sodium channel block (INa 50%) did not increase the difference in phase 1 AP between endocardial and epicardial layers, no ST-segment elevation was observed in the simulated ECG. In contrast, in the case of KCNE3-T4A (Figure 5F) , the same sodium channel block caused the loss of dome of AP in the epicardial layer rather than the endocardial layer, and therefore the simulated ECG showed marked ST-segment elevation, consistent with clinical observation (Figure 1C) .
Discussion
We identified a KCNE3 T4A mutation among 40 consecutive patients with Brugada-pattern ECG. The index patient had experienced several episodes of syncope, possibly due to NMS rather than BrS-related ventricular tachyarrhythmias.
The gain of function of Ito by mutations in genes that encode Ito had been thought to cause BrS. 14, 15 Indeed, an R99H mutation in KCNE3 was recently identified in 1 BrS family. 6 Functional analysis of Ito reconstituted by Kv4.3/KCNE3-R99H showed a gain of function of the channel with a dominantpositive effect. Moreover, the mutation was co-segregated with ECG phenotype. 6 Therefore, the mutation underlies the development of BrS. KCNE3 T4A, the variant identified in the present cohort, could be a candidate for another KCNE3 mutation that is associated with BrS.
We reconstituted Ito by coexpressing Kv4.3 with KCNE3 + KChIP2b in CHO cells, and examined the functional consequence of KCNE3-T4A, because KChIP2 associates with Kv4 and increases Kv4 current with the increase of surface expression of Kv4, by facilitating the trafficking of the channel and the kinetic changes that more resemble native Ito. 35 KCNE3-T4A also increased Ito with a dominant-positive effect. Moreover, computer simulations based on the Ito obtained in electrophysiological recordings demonstrated that KCNE3-T4A recapitulated the ECG phenotype in the present case. These results indicate that KCNE3 T4A could underlie the pathogenesis of Brugada-pattern ECG. Although it may be required to demonstrate a co-segregation of KCNE3 T4A with ECG phenotype to validate that the KCNE3 T4A is associated with Brugada-pattern ECG, we unfortunately could not investigate the patient's family members because of lack of consent. The precise molecular mechanisms of the reverse of KCNE3induced suppression of Kv4.3 by KCNE3-T4A remain to be elucidated. Delpón et al demonstrated, using coimmunoprecipitation techniques, that KCNE3 coassociates with Kv4.3 in human atrial myocardium and rat ventricular myocardium. 6 In addition, Lundby and Olesen reported that KCNE3 has an inhibitory effect on Kv4.3 independent of the presence of KChIP2 in a heterologous expression system. 20 Therefore, although we recapitulated Ito in the presence of KChIP2b, KCNE3-T4A might reverse the KCNE3-induced suppression of Kv4.3 in the absence of KChIP2b, as is the case with KCNE3-R99H reported by Delpón et al. 6 Interestingly, Lundby and Olesen also reported that delayed injection of KCNE3 into Xenopus oocytes can almost completely inhibit Kv4.3 current, suggesting that KCNE3 transcription can act as a regulatory mechanism of the Kv4.3 current density. 20 Further studies of the transcription, trafficking and turnover rate of K4.3 channel and channel complexes in the presence or absence of KChIP2b and KCNE3-WT/T4A, would be required to elucidate the mechanisms of the reverse of KCNE3-induced suppression of Ito by KCNE3-T4A.
Yokokawa et al reported that 35% of patients with Brugadapattern ECG had positive responses during the HUT test, 30 demonstrating a high prevalence of NMS among individuals with Brugada-pattern ECG. Although the autonomic nervous system may play an important role in the development of both BrS and NMS, the precise pathophysiological link between BrS and NMS remains to be elucidated. The identification of a novel SCN5A Q55X mutation in a patient with Brugada-pattern ECG presenting as NMS and the expression of SCN5A in both myocardial cells and intracardiac ganglia raise the possibility of a genetic association between BrS and NMS. 36,37 KCNE3 (MiRP2) is also expressed in not only the heart but also the central nervous system, and it modulates delayed rectifier currents in mammalian neurons by forming native channel complexes with Kv2.1 and Kv3.1b. 38 Taken together, KCNE3 T4A may be associated with both phenotypes of BrS and NMS.
In contrast, we have previously reported that KCNE3 mutations (R99H and T4A) are associated with long QT syndrome (LQTS). 39 A functional analysis of KCNQ1 + KCNE3-R99H coexpression demonstrated a reduction of the repolarizing potassium current, thus supporting the proposition that KCNE3 R99H could be a cause of LQTS. A functional analysis of KCNQ1 + KCNE3-T4A, however, could not demonstrate significant functional abnormalities. Regarding the present case, the QTc interval was not prolonged. Therefore, further studies would be necessary to establish the association between KCNE3 T4A and LQTS. Along with this line, 2 KCNE3 T4A carriers we previously reported had no apparent spontaneous ST-segment elevation in the right precordial ECG leads. 39 One carrier was a 16-year-old boy, much younger than most affected patients, and another was an old woman. Pharmacological provocation tests were not performed to study whether they had Brugada-pattern ECG.
Conclusions
We identified a KCNE3 T4A mutation in a Japanese patient with Brugada-pattern ECG presenting as NMS. Its functional consequence was the gain of function of Ito, which could underlie the pathogenesis of Brugada-pattern ECG. The data provide novel insight into the genetic basis of Japanese BrS. Further studies are required to clarify whether the KCNE3 T4A mutation is also associated with NMS and/or LQTS.
